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Microglial Activation, and Lack of Monocarboxylic Acid
Transporters
Liya Qin and Fulton T. Crews
Background: Wernicke’s encephalopathy-Korsakoff syndrome (WE-KS) is common in alcoholics,
caused by thiamine deficiency (TD; vitamin B1) and associated with lesions to the thalamus (THAL).
Although TD alone can cause WE, the high incidence in alcoholism suggests that TD and ethanol
(EtOH) interact.
Methods: Mice in control, TD, or EtOH groups alone or combined were studied after 5 or 10 days
of treatment. THAL and entorhinal cortex (ENT) histochemistry and mRNAwere assessed.
Results: Combined EtOH-TD treatment for 5 days (EtOH-TD5) showed activated microglia, pro-
inflammatory gene induction and THAL neurodegeneration that was greater than that found with TD
alone (TD5), whereas 10 days resulted in marked THAL degeneration and microglial-neuroimmune
activation in both groups. In contrast, 10 days of TD did not cause ENT degeneration. Interestingly, in
ENT, TD10 activated microglia and astrocytes more than EtOH-TD10. In THAL, multiple astrocytic
markers were lost consistent with glial cell loss. TD blocks glucose metabolism more than acetate. Ace-
tate derived from hepatic EtOH metabolism is transported by monocarboxylic acid transporters
(MCT) into both neurons and astrocytes that use acetyl-CoA synthetase (AcCoAS) to generate cellular
energy from acetate. MCT and AcCoAS expression in THAL is lower than ENT prompting the
hypothesis that focal THAL degeneration is related to insufficient MCT and AcCoAS in THAL. To
test this hypothesis, we administered glycerin triacetate (GTA) to increase blood acetate and found it
protected the THAL from TD-induced degeneration.
Conclusions: Our findings suggest that EtOH potentiates TD-induced THAL degeneration through
neuroimmune gene induction. The findings support the hypothesis that TD deficiency inhibits global
glucose metabolism and that a reduced ability to process acetate for cellular energy results in THAL
focal degeneration in alcoholics contributing to the high incidence of Wernicke-Korsakoff syndrome in
alcoholism.
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THIAMINE DEFICIENCY (TD; vitamin B1) is associ-ated with 2 nervous system ailments, beriberi and Wer-
nicke’s encephalopathy (WE). WE is more common in
alcoholics as it occurs in approximately 1.5% of the general
population with various studies estimating the incidence in
chronic alcoholism ranging from 35% (Cook et al., 1998)
to 80% (Morgan, 1999; Thomson et al., 1987). Although
parenteral thiamine during the early stages can reverse WE
(Caine et al., 1997), many patients with WE will die and
survivors commonly develop Korsakoff syndrome (KS), a
long-lasting amnestic syndrome often requiring institutional-
ization (Kopelman et al., 2009). Alcoholics are at special risk
for TD due to poor diet associated with their lifestyle and
chronic alcoholism compromises dietary thiamine absorp-
tion and activation (He et al., 2006; Martin et al., 2003).
WE-KS amnesia is associated with unique focal lesions
within the thalamus (THAL) and mammillary bodies, com-
ponents of an emotional circuit of Papez that includes nodes
in hippocampus, coursing to the mammillary bodies, the
THAL, cingulum, entorhinal cortex (ENT), and returning to
the hippocampus (Sullivan and Pfefferbaum, 2009). Interest-
ingly, a large Australian postmortem neuropathological
study of TD focal lesions found 1.7% of the general popula-
tion had focal lesions consistent with TD, alcoholics repre-
sented 88% of those with TD-like lesions, but only 20%
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were diagnosed with WE, which is consistent with unique
factors in alcoholism contributing to WE-KS. The reasons
for the high frequency of TD neuropathology in alcoholism
and the mechanisms of TD-induced brain focal neurodegen-
eration leading toWE-KS are not fully understood.
Dietary thiamine is converted to the co-enzyme thiamine
pyrophosphate, which is essential for energy production via
glucose metabolism through complexes involving pyruvate
kinase, transketolase, and alpha-ketoglutarate dehydroge-
nase. Loss of enzyme activity due to TD results in degrada-
tion of proteins and TD reduces transketolase enzymatic
activity and protein levels in both the liver and the brain
(Jung et al., 1991), further confounding the mechanisms of
TD-induced focal brain degeneration. Gene expression
studies of human alcoholic brain find reduced levels of trans-
ketolase gene expression (Liu et al., 2006) and decreased
transketolase protein in alcoholic brain (Alexander-Kaufman
et al., 2006). Brains of alcoholics with WE-KS have reduced
alpha-ketoglutarate dehydrogenase (Hazell and Butterworth,
2009) consistent with alcoholism and TD leading to reduc-
tions in brain levels of these enzymes.Multiple animal studies
have used a TD model that includes a thiamine-deficient diet
combined with pyrithiamine, which blocks thiamine activa-
tion. Treatment with this TDmodel for about 14 days results
in focal brain lesions to the THAL and other brain regions
modeling human WE-KS neuropathology and further estab-
lishing TD as the principle cause of the focal pathology (Haz-
ell and Butterworth, 2009; Hazell et al., 2010). Recent studies
found that TD-inducedMCP-1, a proinflammatory cytokine,
and thatMCP-1 inhibition or transgenic knockouts ofMCP-
1 reduce TD-induced THAL degeneration (Yang et al.,
2011). We found that postmortem human alcoholic brain has
elevated levels of MCP-1 (He and Crews, 2008) and that
chronic ethanol (EtOH) treatment of mice (Qin et al., 2008)
and rat brain slices (Zou and Crews, 2010) increases expres-
sion of MCP-1. To test the hypothesis that EtOH induction
of MCP-1 and other proinflammatory signals would potenti-
ate TD toxicity, we treated mice with EtOH in combination
with the TD-WEmodel and investigated a prepathology time
point providing insight into the progression of THAL lesions.
Further, we compared THALwith ENT, 2 nodes of the emo-
tional circuit thought to underlie WE-KS that differ in
response to TD.
TD disrupts cellular energy formation and glucose metab-
olism while alcohol provides a source of energy independent
of glucose, for example, acetate. Alcohol (EtOH) is metabo-
lized by the liver to acetate, which provides the liver with
energy. Acetate is released into the blood reaching concen-
trations in the low millimolar range (Sarkola et al., 2002)
that can provide energy to tissues. However, cells require
monocarboxylic acid transporters (MCT) to transport ace-
tate into the cell where acetate can be oxidized for energy
(Halestrap andWilson, 2012). Alcoholics and heavy drinkers
have much higher plasma acetate levels than controls (Korri
et al., 1985), and heavy drinkers appear to have an increased
capacity for brain acetate metabolism (Jiang et al., 2013).
Recent studies of brain acetate transport and metabolism
find acetate distribute in brain volume consistent with distri-
bution to glia and extracellular space (Patel et al., 2010).
Further, imaging of brain glucose utilization finds that alco-
holics have lower brain glucose metabolism than can be
explained by decreased neuronal activity, suggesting alco-
holic brain metabolizes more acetate and less glucose than
controls (Volkow et al., 2006). EtOH treatment of rats
decreases brain glucose metabolism (Learn et al., 2003) and
increases cortical acetyl-CoA synthetase (AcCoAS) activity
(Kiselevski et al., 2003), the key enzyme initiating acetate
oxidation, supporting the hypothesis that alcoholism leads
to an increase in brain acetate metabolism reducing brain
glucose requirements. Hepatic oxidation of EtOH to acetate
does not require thiamine-dependent enzymes. Thus, acetate
formed from alcohol can be transported into brain and as-
trocytes by MCT, providing an important brain energy
source for alcoholics and heavy drinkers. We report here that
MCT required for acetate metabolism in brain are expressed
at much lower levels in THAL, which degenerates during
Table 1. Summary of Antibodies Used in This Study
Antibody Manufacturer Host Species detected Dilution Application
NeuN Chemicon International Mouse Mouse 1:500 IHC
Iba1 Wako Pure Chemical Industries, Ltd
(1–2Doshomachi 3-Chome Chuo-ku
Osaka 540–8605, Japan)
Rabbit Mouse 1:1,000 IHC
Glial fibrillary acidic protein DakoCytomation (Glostrup, Denmark) Rabbit Mouse 1:500 IHC
Gl Syn (GS, FL-373) Santa Cruz Biotechnology (Santa Cruz, CA) Rabbit Mouse 1:200 IHC
EAAT1 (N-19) Santa Cruz Biotechnology Goat Mouse 1:200 IHC
ACSS1 (V-16) Santa Cruz Biotechnology Rabbit Mouse 1:50 IHC
MCT1 (T-19) Santa Cruz Biotechnology Goat Mouse 1:100 IHC, WB
MCT1 (T-19) P Santa Cruz Biotechnology Blocking peptide Mouse 0.2 lg/ml WB
MCT2 (M-17) Santa Cruz Biotechnology Goat Mouse 1:100 IHC, WB
MCT2 (M-17) P Santa Cruz Biotechnology Blocking peptide Mouse 0.2 lg/ml WB
b-Actin Cell Signaling Technology (Danvers, MA) Rabbit Mouse 1:500 WB
IHC, immunohistochemistry; WB, Western blotting; EAAT1, excitatory amino acid transporter; GS, glutamine synthetase; MCT, monocarboxylic acid
transporters.
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TD, than in ENT, which does not show marked degenera-
tion with TD. Further, we find that acetate supplementation
can blunt TD-induced THAL degeneration.
MATERIALS ANDMETHODS
Animals
Eight-week-old male (20–22 g) C57BL/6 mice were purchased
from Jackson Laboratories (Bar Harbor, ME). The reagents and
antibodies used in this study are listed in Table 1. All protocols in
this study were approved by the Institutional Animal Care and Use
Committee and were in accordance with the National Institute of
Health regulations for the care and use of animals in research.
Reagents
Fluoro-Jade B was from Chemicon International (Temecula,
CA). Pierce Bicinchoninic Acid (BCA) protein assay kit was from
Thermo Scientific (Rockford, IL). The SYBR green PCR kit was
purchased from Applied Biosystems (Foster City, CA). Mouse
TNFa, IL-1b, IL-6, and mouse JE/MCP-1 commercial enzyme-
linked immunosorbent assay (ELISA) kits were purchased from
R&D Systems (Minneapolis, MN). All other reagents were pur-
chased from Sigma-Aldrich Corporation (St. Louis, MO). Antibod-
ies used in this study are shown in Table 1.
Animal Treatments
Male C57BL/6 mice were allowed to acclimate for 5 days and
then randomly divided into normal chow control (control),
EtOH + normal chow (5 g/kg, i.g., EtOH, daily for 10 days), thia-
mine-deficient diet (TD control), thiamine-deficient diet + pyrithi-
amine (0.5 mg/kg, i.p., TD), and EtOH + thiamine-deficient
diet + pyrithiamine (EtOH-TD).Mice in TD and EtOH-TD groups
received a thiamine-deficient diet (MP Biomedicals, Solon, OH) ad
libitum, and daily intraperitoneal injection of the thiamine pyro-
phosphokinase inhibitor, pyrithiamine hydrobromide, at a dose of
0.5 mg/kg body weight in normal saline for 5 days (days 6 to 10,
TD5) or 10 days (TD10). For EtOH and EtOH-TD groups, mice
were treated intragastrically with EtOH (5 g/kg, i.g., 25% EtOH w/
v) daily 30 minutes before saline or pyrithiamine hydrobromide
treatment. Average level of blood alcohol at 1 hour after the first
and last EtOH treatments was 290  11 mg/dl (w/v, n = 10) and
Table 2. BodyWeight
Before treatment After treatment
(A) EtOH-TD experiment
Control 23.61  0.41 23.99  0.37
TD5 23.08  0.47 23.10  0.47
EtOH 23.99  0.38 21.38  0.66**
EtOH-TD5 23.64  0.38 20.96  0.41**
TD10 23.43  0.31 21.14  0.56**
EtOH-TD10 23.60  0.32 19.80  0.27**
(B) GTA-TD10 experiment
Control 23.74  0.39 23.24  0.39
GTA 23.40  0.57 22.91  0.47
TD10 23.37  0.39 19.95  0.41**
GTA-TD10 23.61  0.38 21.11  0.50**
EtOH, ethanol; GTA, glycerin triacetate; TD, thiamine deficiency.
**p < 0.01 compared with vehicle control group.
Values are the mean  SEM of grams of body weight.
Table 3. Real-Time PCR Primers
Mouse primer pairs
TNFa 5′-GACCCT CACACT CAG ATC ATC TTC T-3′
5′-CCT CCA CTTGGTGGT TTGCT-3′
IL-1b 5′-CTGGTG TGT GACGTT CCC ATT A-3′
5′-CCG ACAGCA CGAGGC TTT-3′
IL-6 5′-GGCCTT CCC TAC TTC ACA AG-3′
5′-ATT TCC ACG ATT TCC CAGAG-3′
MCP-1 5′-ACT GAA GCC AGCTCT CTC TTC CTC-3′
5′-TTC CTT CTT GGGGTCAGC ACAGAC-3′
b-Actin 5′-GTA TGACTC CAC TCA CGGCAA A-3′
5′-GGT CTC GCT CCT GGA AGA TG-3′
Fig. 1. Chronic ethanol (EtOH) increases thiamine deficiency (TD)-
induced microglial activation. C57BL/6 mice were treated with vehicle,
EtOH, TD (thiamine deficiency) for 5 days (TD5), TD for 10 days (TD10),
EtOH+TD5, and EtOH+TD10 as described in Materials and Methods. Ani-
mals were sacrificed 24 hours following the last dose of EtOH treatment
(5 g/kg, i.g. daily for 10 days). Brain sections were immunostained with
Iba1 microglial antibody. (A) Microglia in control and TD5 groups were
showed resting morphology. Some of microglia in EtOH alone group were
slightly activated. All the microglia in combined EtOH and TD5 treatment
were significantly activated. (B) Microglia in control group were in resting
state. Microglia in TD10 treatment showed many busy “activated” morphol-
ogy. EtOH+TD10 group, microglia were dramatically activated, a maximal
stage of activation. The images presented are representative of 3 indepen-
dent experiments. Scale bar = 50 lM. Inset scale bar = 10 lM.
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296  15 mg/dl (w/v, n = 10), respectively. The blood EtOH level
is high and considered to model binge drinking.Mice were sacrificed
24 hours following the last dose of EtOH, and their brains and sera
were used for either morphological or biochemical (mRNA and
protein) analyses.
In the study of acetate (glycerin triacetate [GTA]) supplementa-
tion, 28 mice were randomly divided into 4 groups (n = 7 per
group): control group, GTA group, TD10 group, and GTA-TD10
group. Controls and TD groups were treated as described above.
On day 1, GTA animals received a single dose of 4 g/kg GTA i.g.,
and 3 animals died prompting a change to 2 daily doses of 2 g/kg
GTA i.g. to maintain the 4 g/kg/d dose for the remaining 9 days.
Mice in GTA-TD group received 2 doses of GTA (2 g/kg/dose, i.e.,
4 g/kg/d, i.g.) at 8:00 AM and 4:00 PM and received pyrithiamine
hydrobromide (0.5 mg/kg, i.p.) 30 minutes after the second dose of
GTA for 10 days and sacrificed 24 hours after the last dose of TD
treatment. Body weights are shown in Table 2.
Real-Time PCR Analysis
Total RNA was extracted from the mouse whole brain samples
24 hours after the last dose of EtOH treatment and used for reverse
transcription PCR analysis as described previously (Qin and Crews,
2012). The primer sequences used in this study are shown in
Table 3.
Immunohistochemistry
Brains were fixed in 4% paraformaldehyde and processed for
immunostaining as described previously using the antibodies listed
in Table 1. Images were captured on an Olympus BX51 microscope
(Olympus Corporation of the Americas, Center Valley, PA) and
Sony DXC-390 video camera (Sony Electronics Inc., Broadcast and
Professional Company, Park Ridge, NJ). For NeuN+IR cell count-
ing, a stereological method was used to quantify cells within the
THAL and ENT following NeuN immunostaining of brain sections
using the Computer Assisted Stereological Toolbox stereological
system as described previously (Crews et al., 2013). Cell counts for
the GTA experiment used a modified stereology profile count as
described previously (Crews et al., 2004). Quantification of acti-
vated Iba1 + IR and GFAP + IR cells was performed and
expressed as percent activated [(activated cells/mm2)/(total + IR
cells/mm2) 9 100%] as described previously (Qin and Crews, 2012).
Western Blots, Fluoro-Jade B Staining, and ELISA
For Western blots, brains were cut into 300 lM of slices on a
vibrating microtome, THAL and ENT were dissected and homoge-
nized in lysis buffer (RIPA buffer; Sigma) containing 0.1 ml of pro-
tease inhibitor cocktail (Sigma) per 10 ml of lysis buffer, centrifuged
and prepared for Western blotting as described previously (Crews
Fig. 2. Chronic ethanol (EtOH) increases thiamine deficiency (TD)-induced gene expression of TNFa, IL-1b, IL-6, and MCP-1. C57BL/6 mice were
treated with vehicle, EtOH, TD5, TD10, EtOH+TD5, and EtOH+TD10 as described in Materials and Methods. Animals were sacrificed 24 hours following
the last dose of EtOH treatment (5 g/kg, i.g. daily for 10 days). Brain TNFa, IL-1b, IL-6, and MCP-1 mRNA were measured by real-time PCR. EtOH alone
significantly increased gene expression of TNFa, IL-6, and MCP-1. TD5 did not show any increases in TNFa, IL-1b, and MCP-1 mRNA, but did show sig-
nificant increase in IL-6 mRNA. Ten days of TD treatment significantly enhanced gene expression of TNFa, IL-1b, IL-6, and MCP-1. In both EtOH+TD5
and EtOH+TD10 groups, TNFa, IL-1b, IL-6, and MCP-1 mRNA was significantly increased, compared with vehicle control group. *p < 0.05, **p < 0.01,
compared with the vehicle controls. #p < 0.05, compared with 5 days of TD (TD5) treatment.
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et al., 2013). To verify MCT1 and MCT2+ immunoreactive (+IR)
bands, MCT1 and MCT2 antibodies were pre-absorbed with the
corresponding MCT1 andMCT2 peptides (0.2 lg/ml). Fluoro-Jade
B used mouse brain sections in distilled water mounted on super-
frost plus microscope slides processed as described previously (Qin
and Crews, 2012). ELISA for TNFa, IL-1b, IL-6, and MCP-1 used
frozen brains and mouse JE/MCP-1 commercial ELISA kits from
R&D Systems, as described previously (Crews et al., 2013).
Statistical Analysis
Statistical analysis was performed using StatView (SAS Institute,
Cary, NC). For all, analysis of variance (ANOVA) was conducted,
followed by Bonferroni correction for multiple comparisons. For
each analysis, the Bonferroni-corrected p-value was based on the
following formula: a = 0.05/# of comparisons. For instance, for the
4 groups of GTA experiment, the corrected p-value was 0.01
(a = 0.05/5). A value of p < 0.01 was considered statistically signifi-
cant. All values are reported as mean  SEM.
RESULTS
To determine whether EtOH contributed to TD-induced
neuroimmune activation and neurotoxicity, we assessed mi-
croglial activation (Fig. 1), mRNA (Fig. 2), and protein
(Fig. 3) levels of proinflammatory cytokines TNFa, IL-1b,
IL-6, and MCP-1 and cell death (Fig. 4). Our initial studies
involved multiple groups of animals, including normal chow
control (control), EtOH + normal chow (5 g/kg, i.g., EtOH,
daily for 10 days), thiamine-deficient diet alone, and with
EtOH, thiamine-deficient diet + pyrithiamine (0.5 mg/kg,
i.p., TD), and EtOH + thiamine-deficient diet + pyrithi-
amine (EtOH-TD). We found no effect of thiamine-
deficient diets after 5 or 10 days of treatment (not shown)
and focused our studies on the widely used WS model using
thiamine-deficient diet + pyrithiamine (TD) (Sullivan and
Pfefferbaum, 2009). In Figs 4 and 5, we show images of
groups showing changes compared with control representing
other groups showing no change. Microglial activation was
assessed morphologically. We found that the THAL of con-
trol (Fig. 1A,B) showed ramified “resting” healthy brain mi-
croglial morphology. EtOH alone and TD5 alone treatment
showed enlarged microglia and TD10 alone treatment
showed many bushy “activated” morphology microglia
(Fig. 1). EtOH-TD5 (5 days combination treatment) and
EtOH-TD10 groups showed many phagocytic macrophage-
like microglia, a maximal stage of activation. Proinflamma-
tory cytokine levels showed graded increases consistent with
microglial activation findings. EtOH alone treatment
increased TNFa, MCP-1, and IL-6 mRNA whereas TD5
alone only increased IL-6 mRNA (Fig. 2). Combined EtOH-
Fig. 3. TD10 and EtOH-TD10 increase production of TNFa, IL-1b, IL-6, and MCP-1 protein. C57BL/6 mice were treated with vehicle, EtOH, TD10,
and EtOH+TD10 as described in Materials and Methods. Animals were sacrificed 24 hours following the last dose of EtOH treatment (5 g/kg, i.g. daily for
10 days). Brain TNFa, IL-1b, IL-6, and MCP-1 protein was measured by enzyme-linked immunosorbent assay. EtOH increased TNFa, IL-6, and MCP-1
production. TD10 and EtOH+TD10 significantly increase production of TNFa, IL-1b, IL-6, and MCP-1 protein.*p < 0.05, **p < 0.01, compared with the
vehicle control group. TD, thiamine deficiency.
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TD5 treatment increased IL-1b as well as TNFa, MCP-1,
and IL-6 mRNA with most being greater than EtOH or TD
alone treatment (Fig. 2). All treatments for 10 days (e.g.,
EtOH, TD10, and EtOH-TD10) increased proinflammatory
cytokine mRNA (Fig. 2) and protein (Fig. 3) expression.
Thus, EtOH, TD, and EtOH-TD caused microglial activa-
tion and induction of proinflammatory cytokines that pro-
gressively increase during TD treatment from 5 to 10 days.
Microglial activation and proinflammatory cytokine induc-
tion is greater in the combined EtOH-TD treatment at
5 days consistent with EtOH accelerating and/or potentiat-
ing TD-induced neuroimmune activation.
To investigate cell death, we used Fluoro-Jade B (FJ+), a
stain used to identify degenerating and dying cells. Further,
to better understand the focal degeneration of THAL by TD,
we followed THAL at 5 and 10 days of TD treatment
(Fig. 4A). As expected, controls showed almost no FJ+ cells.
EtOH alone show few FJ+ cells. TD10 shows a number of FJ+
cells, more than TD5 (Fig. 4A). Combined EtOH-TD treat-
ment showed many FJ+ cells in THAL after 5 days of TD that
increases after 10 days of TD treatment. These findings support
our model of WE-KS as causing TD-induced focal THAL
degeneration that is associated with microglial activation and
that EtOH increases TD-induced THALdegeneration.
To further investigate the focal nature of TD-induced
THAL degeneration, we compared responses in THAL to
ENT. Although large numbers of FJ+ cells were found in the
THAL of EtOH-TD10-treated animals, there were few, if
any, FJ+ cells in the ENT of EtOH-TD10-treated animals
(Fig. 4B). A comparison of sections stained for NeuN, a
nuclear neuronal marker protein, found that ENT neurons
were not altered by EtOH-TD10 treatment, whereas THAL
NeuN+IR neurons were decreased by 15% by EtOH-TD5
and reduced 43% in THAL of EtOH-TD10 groups, respec-
tively (Fig. 5). Although EtOH-TD10 treatment increased
THAL microglial activation more than TD10 alone (Figs 1
and 6), in ENT TD10 alone caused more microglial activa-
tion than EtOH-TD10, although ENT shows much lower
overall microglial activation. ENT microglial morphological
activation using Iba1 + IR cells/mm2 (Fig. 6) finds 61  2%
activated in TD, 16  1% activated in EtOH+TD (p < 0.01
vs. TD alone; controls 4  0.1; p < 0.01 vs. TD, and
EtOH+TD) consistent with EtOH reducing TD-induced
microglial activation in ENT, but increasing it in THAL.
Regardless, THAL microglial morphology, Fluoro-Jade B
and NeuN+IR findings support a proinflammatory mecha-
nism involved in focal THAL degeneration that is not found
in the ENT.
To investigate the response of astrocytes to TD, we
compared THAL and ENT using astrocyte markers glial
fibrillary acidic protein (GFAP) (Fig. 7), glutamine synthe-
tase (GS) (Fig. 8), and the excitatory amino acid transporter
(EAAT1) (Fig. 9). In general, ENT astrocyte marker protein
expression, for example, GFAP+IR, GS+IR, and EAAT1 +
IR appears more robust than that found in THAL. EtOH-TD10
induced a loss of THAL astrocytes markers, consistent with TD-
induced focal THAL degeneration involving toxicity to both neu-
rons and astrocytes. Interestingly, astrocyte GFAP shows darker
staining in TD10, in both THAL and ENT, but not in EtOH-
TD10. In THAL, EtOH-TD10 has a few dark stained cells but a
general loss, whereas in ENT, EtOH-TD10 shows GAFP + IR
cell morphology more like controls than TD10 (Fig. 7). Quantifi-
cation of GFAP + IR cells/mm2 morphological activation finds
59  6% activated in TD, 17  2% activated in EtOH + TD
(p < 0.01 vs. TD alone; controls 2  0.4; p < 0.01 vs. TD and
EtOH + TD) consistent with EtOH reducing the TD astrocyte
insult in ENT that contrasts with EtOH increasing microglial
activation in THAL.
MCT transport acetate, lactate, and other monocarboxylic
acids across the blood–brain barrier and into cells (Pellerin
Fig. 4. Chronic ethanol (EtOH) increases thiamine deficiency (TD)-
induced Fluoro-Jade B positive staining in the thalamus (THAL) of C57BL/
6 mice. Brain sections were stained with Fluoro-Jade B as described in
Materials and Methods. (A) Representative images for Fluoro-Jade B
labeling are from THAL of C57BL/6 mice treated with Control (vehicle,
10 days; Control 10), EtOH 10, TD5, EtOH+TD5, TD10, and EtOH+TD10.
Control 10 and groups showing Fluoro-Jade B positive staining is shown.
Groups with no staining are similar to control 10. EtOH potentiates TD5-
and TD10-induced Fluoro-Jade B positive staining, suggesting cell death.
(B) Images are from vehicle and EtOH+TD10-treated groups. EtOH+TD10
induces Fluoro-Jade B positive cell death in THAL, but not in entorhinal
cortex (ENT). No Fluoro-Jade B positive staining is found in ENT for all
groups as shown for Control 10 and EtOH+TD10. THAL control and
EtOH+TD10 groups shown are the same groups as shown in A. Scale
bar = 50 lm.
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et al., 1998). There are multiple forms of MCT, for example,
MCT1 and MCT2. MCT in THAL and ENT were com-
pared in control animals to determine whether differences in
the neurotoxic response to TD were related to differences in
basal expression of transporters and enzymes related to using
acetate for energy. Brain region dissection followed by Wes-
tern blot indicated MCT1 and MCT2 proteins were
expressed at about 3-fold higher levels in ENT than THAL
under control conditions as compared to b-actin, a global
cell protein (Fig. 10A). MCT1 + IR and MCT2 + IR were
greater in ENT than THAL (Fig. 10B,C). EtOH treatment
did not markedly alter MCT1 + IR and MCT2 + IR in
ENT, whereas in THAL MCT1 + IR and MCT2 + IR are
reduced likely due to cell loss. Further, we assessed AcCoAS,
an enzyme that forms acetyl-CoA from acetate, which is crit-
ical for cellular energy from acetate. AcCoAS is not thia-
mine-dependent and is activated by acetate (Hallows et al.,
2006). In ENT microglial (Fig. 6) and astrocyte (Fig. 7) acti-
vation morphology are greater in TD10 alone compared with
EtOH-TD10. This is consistent with EtOH reducing the TD
insult in ENT, but not THAL, due to ENT having greater
amounts of MCT and AcCoAS needed for cellular energy
from acetate (see Figs 10 and 11). The findings that ENT-
TD10, that is, TD alone, shows greater microglial and astro-
cyte activation morphology than ENT-EtOH-TD10, EtOH
combined with TD, treated animals are consistent with
Fig. 5. Ethanol (EtOH)-thiamine deficiency (TD) induces neuronal death in thalamus (THAL), but not in entorhinal cortex (ENT). C57BL/6 mice were
treated with vehicle, EtOH+TD5 and EtOH+TD10 as described in Materials and Methods. Animals were sacrificed 24 hours following the last dose of
EtOH treatment (5 g/kg, i.g. daily for 10 days). Brain sections were immunostained with NeuN neuronal antibody. (A) EtOH+TD5 and EtOH+TD10
induced 15 and 43% of loss of NeuN+IR cells in THAL, respectively, compared with vehicle controls, but both treatments did not show any difference in
ENT. (B) Representative images for NeuN+IR cells from ENT and THAL of C57BL/6 mice treated with vehicle and EtOH+TD10. Black arrows in
EtOH+TD10 (bottom left) outline THAL area showing neurodegeneration in the THAL. *p < 0.05, **p < 0.01, compared with the corresponding vehicle
control mice. It is difficult to visualize lost nuclei; however, we show low magnification images of controls and EtOH-TD to illustrate the extent of the tha-
lamic damage and higher magnification to allow the reader to see the dramatic loss of neuronal nuclei from the TD THAL. No groups show damage in
ENT, so the 2 images shown are representative of all groups.
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EtOH, perhaps acetate derived from EtOHmetabolism, pro-
tecting against TD-induced ENT damage.
To determine whether acetate could protect from TD10-
induced THAL pathology, we administered GTA, which has
been shown to increase blood acetate levels to the millimolar
range (Reisenauer et al., 2011). We treated mice with GTA
with or without TD10 and assessed THAL toxicity (Fig. 12).
Microglial activation assessed by Iba1 + IR showed marked
activation phagocytic morphology in the TD group, that was
reduced to “bushy” activated microglial phenotypes in the
GTA-TD group, but not to ramified “resting” morphology
as seen in controls (Fig. 12A, top). Degeneration assessed by
Fluoro-Jade B or NeuN+IR both indicated GTA protected
the THAL from TD-induced degeneration. This group of
TD animals showed marked Fluoro-Jade green areas of
degeneration as well as individual dying neurons (insets
middle Fig. 12A). In general, GTA protected against TD
toxicity; however, there was variation within the TD and
GTA-TD groups with some GTA-TD animals completely
protected and others showing modest protection. The TD10-
induced loss of neurons is clearly seen with NeuN+IR
(Fig. 12A) where only a few nuclei remain. Quantification of
both Fluoro-Jade B and NeuN+IR indicated TD-induced
degeneration was reduced by GTA (Fig. 12B). These find-
ings indicate that acetate can be used by the brain to protect
against TD-induced toxicity. Together, the findings suggest
the focal TD-induced THAL degeneration can be reduced
by elevated acetate levels consistent with the hypothesis that
focal THAL degeneration is due to the TD metabolic insult
to glucose metabolism combined with a reduced ability of
THAL cells to use acetate for energy.
DISCUSSION
We report here that 5 days of TD alone treatment resulted
in few markers of THAL pathology, but EtOH treatment
combined with TD for 5 days shows significant increases in
TD-induced THAL microglial activation and induction of
brain proinflammatory cytokine, mRNA, and protein
increases in neuronal death markers, and decreased neuro-
Fig. 6. Ethanol (EtOH)-thiamine deficiency (TD) induces microglial acti-
vation in thalamus (THAL), but not in entorhinal cortex (ENT). C57BL/6
mice were treated with vehicle and EtOH+TD10 as described in Materials
and Methods. Animals were sacrificed 24 hours following the last dose of
EtOH treatment (5 g/kg, i.g. daily for 10 days). Brain sections were immu-
nostained with Iba1microglial antibody. Microglia (Iba1 + IR) were in resting
morphology in ENT of mice treated with both vehicle and EtOH+TD10.
However, EtOH+TD10-treated THAL had dramatic microglial activation
showed by enlarged cell body and intensified Iba1 staining, compared with
vehicle controls. Microglia in TD alone treatment showed activated morphol-
ogy in ENT, compared with EtOH+TD10-treated ENT. Scale bar = 50 lm.
Fig. 7. EtOH-thiamine deficiency (TD) induces astroglial activation in
thalamus (THAL), but not in entorhinal cortex (ENT). C57BL/6 mice were
treated with vehicle and EtOH+TD10 as described in Materials and Meth-
ods. Animals were sacrificed 24 hours following the last dose of EtOH
treatment (5 g/kg, i.g. daily for 10 days). Brain sections were immuno-
stained with glial fibrillary acidic protein (GFAP) astrocyte antibody. Astro-
glia (GFAP+IR) were in resting morphology in ENT of mice treated with
both vehicle and EtOH+TD10. However, EtOH+TD10-treated THAL
showed significant astroglial activation showed by enlarged GFAP+IR cells
and intensified GFAP staining, compared with vehicle controls. Astroglia in
TD alone treatment showed activated morphology in ENT, compared with
EtOH+TD10-treated ENT. Scale bar = 50 lm.
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nal density. Combined EtOH-TD-induced loss of THAL
neuronal marker NeuN+IR and increases in Fluoro-Jade B+
cell death marker are consistent with EtOH accelerating neu-
roimmune gene induction and microglial activation that con-
tribute to neuronal death. We have previously found that
chronic EtOHprimes microglial and neuroimmune responses
in mice (Qin et al., 2008) and in vitro in rat brain slice cul-
tures (Zou and Crews, 2010). Chronic EtOH treatment of
mice has been found to potentiate both the systemic and
brain proinflammatory cytokine responses to the Toll-like
receptor 4 (TLR4) agonist lipopolysaccharide (Qin et al.,
2008) and the TLR3 agonist PolyI:C (Qin and Crews, 2012).
Further, we found postmortem human alcoholic brain has
elevated levels of microglial markers and the cytokine MCP-
1 (He and Crews, 2008). Interestingly, inhibition of MCP-1
or transgenic knockouts of MCP-1 protect mice from TD-
induced THAL degeneration (Yang et al., 2011) consistent
with neuroimmune gene activation contributing to TD-
induced THAL degeneration. Recent studies have indicated
chronic EtOH primes neuroimmune proinflammatory
responses due to increased expression of neuroimmune sig-
naling molecules including HMGB1 and its receptors, for
example, TLRs, that contribute to positive loops of proin-
flammatory gene induction (Crews et al., 2013). These find-
ings support the hypothesis that EtOH proinflammatory
priming accelerates TD-induced THAL degeneration
(Fig. 13).
Chronic EtOH is known to mildly increase expression of
brain innate immune genes (Crews and Vetreno, 2011). We
report here no effect of TD5 on MCP-1 mRNA, but found a
significant increase in MCP-1 mRNA by EtOH alone that
was further increased by EtOH-TD5 treatment. These find-
ings suggest neuroimmune activation accelerates THAL
degeneration, which is consistent with studies reporting mi-
nocycline inhibition of microglial activation delays TD alone
thalamic pathology (Wang and Hazell, 2010). Our finding of
THAL focal degeneration during EtOH-TD treatment is
consistent with previous studies that assessed TD alone. Pre-
vious studies following THAL NeuN+cells (Ke et al., 2003)
or ataxia (Vetreno et al., 2012) find 10 to 15 days of TD
treatment that leads to permanent damage. We did not find
THAL neuronal loss or microglial activation after 5 days of
TD alone treatment, whereas EtOH-TD5 shows signs of
THAL neurodegeneration including a loss of NeuN+IR
cells, increased cytokine mRNA, protein, and microglial
morphology changes. Our findings in mice are entirely con-
sistent with the elegant rat studies of Hazell on TD alone
THAL degeneration (Hazell and Butterworth, 2009; Hazell
et al., 2010). TD alone in rats (14 days) causes THAL neuro-
nal degeneration, loss of astrocyte markers GFAP, GS, and
glutamate transporters, although it is difficult to distinguish
loss of astrocyte markers from loss of astrocytes. However,
activated astrocytes increase GFAP expression suggesting
loss of markers represents astrocyte degeneration. Regard-
less, our findings and multiple TD alone studies are consis-
tent with astrocyte dysfunction contributing to THAL focal
neurodegeneration (Hazell and Butterworth, 2009; Hazell
et al., 2010). Thus, TD-induced THAL neurodegeneration
involves astrocyte dysfunction that contributes to the TD
metabolic insult. EtOH neuroimmune activation in glia likely
Fig. 8. Ethanol (EtOH)-thiamine deficiency (TD) reduces glutamine
synthetase (GS) immunoreactivity in thalamus (THAL), but not in entorhi-
nal cortex (ENT). C57BL/6 mice were treated with vehicle and EtOH+TD10
as described in Materials and Methods. Animals were sacrificed 24 hours
following the last dose of EtOH treatment (5 g/kg, i.g. daily for 10 days).
Brain sections were immunostained with GS astrocyte antibody.
EtOH+TD10 did not alter GS+IR in ENT; however, GS+IR was significantly
reduced in THAL, compared with vehicle controls. Scale bar = 50 lm.
Fig. 9. Ethanlol (EtOH)-thiamine deficiency (TD) reduces excitatory
amino acid transporter (EAAT1) immunoreactivity in thalamus (THAL), but
not in entorhinal cortex (ENT). C57BL/6 mice were treated with vehicle and
EtOH+TD10 as described in Materials and Methods. Animals were sacri-
ficed 24 hours following the last dose of EtOH treatment (5 g/kg, i.g. daily
for 10 days). Brain sections were immunostained with astrocytic glutamate
transporter EAAT1 antibody. EAAT1 immunoreactivity did not show any
change in ENT between vehicle and EtOH+TD10 groups. However,
EtOH+TD10 treatment significantly decreased EAAT1 + IR cells in THAL,
compared with vehicle controls. Scale bar = 50 lm.
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Fig. 10. Monocarboxylic acid transporters (MCT1) and MCT2 expressions in Western blot and immunohistochemistry. (A) Thalamus (THAL) and en-
torhinal cortex (ENT) regions were dissected, and Western blot was performed as described in Methods. ENT shows more MCT1 and MCT2 protein
expressions than THAL in untreated C57BL/6 mice. (B) C57BL/6 mice were treated with vehicle and EtOH+TD10 as described in Materials and Methods.
Animals were sacrificed 24 hours following the last dose of EtOH treatment (5 g/kg, i.g. daily for 10 days). Brain sections were immunostained with
MCT1 and MCT2 antibodies. EtOH+TD10-treated THAL showed decreased MCT1 + IR (B) and MCT2 + IR (C) cells, compared with the corresponding
ENT. *P < 0.05, compared with ENT region. Scale bar = 50 lm.
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contributes to EtOH acceleration of THAL neuronal degen-
eration (Fig. 13).
TD causes a mild metabolic insult due to loss of a cofactor
made from thiamine required for key enzymes in glucose
metabolism, that is, pyruvate dehydrogenase, transketolase
and alpha-ketoglutarate dehydrogenase, with loss of cofac-
tor inhibiting enzyme activity and promoting degradation of
the proteins (Gibson and Blass, 2007). Unique factors appear
to induce focal THAL degeneration because TD alone
reduces transketolase activity and protein more in the liver
than in the brain (Jung et al., 1991) suggesting that the entire
organism is insulted by TD inhibition of glucose metabolism.
TD alone progressively insults multiple brain regions (Vet-
reno et al., 2012), with THAL among the most sensitive to
degeneration. TD-induced acute WE can be fatal as would
be expected from compromised glucose metabolism. WE-KS
in humans is associated with alcoholism and unique focal
lesions within components of an emotional circuit of Papez
that includes THAL, mammillary bodies, cingulum, ENT,
and the hippocampus (Sullivan and Pfefferbaum, 2009). We
studied THAL and ENT confirming TD focal pathology in
THAL, but not ENT. Although our findings support EtOH
priming of neuroimmune responses as accelerating TD-
induced THAL neurodegeneration these findings do not
address the focal nature of TD-induced neurodegeneration.
We hypothesized that the global metabolic insult of TD
was modified by EtOH, which provides significant metabolic
energy independent of glucose (Fig. 13). EtOH metabolism
to acetate increases liver energy. Alcohol decreases brain glu-
cose metabolism, consistent with the brain switching from
glucose to acetate derived from EtOH as a source of energy
(Volkow et al., 2006). Studies in humans (Volkow et al.,
2013) and rats (Pawlosky et al., 2010) indicate that EtOH
and/or acetate reduce brain glucose metabolism. In humans,
acute EtOH intoxication decreased whole brain glucose
metabolism, but the smallest reduction was in THAL, consis-
tent with a reduced ability of THAL to metabolize acetate
(Volkow et al., 2013). Acetate has been found to reduce
EtOH induction of hepatic proinflammatory cytokines and
to up-regulate AcCoAS, a key enzyme in acetate energy
metabolism (Kendrick et al., 2010). Acetate from EtOH
metabolism is released into the blood during binge drinking
providing an energy substrate for multiple tissues, including
brain (Fig. 13) (Waniewski and Martin, 2004) and reducing
glucose requirements (Jiang et al., 2009). Hepatic EtOH
metabolism increases blood acetate to about 2 mM (Nicho-
las et al., 2008). MCT1 and MCT2 have acetate Km of 2.2
and 2.6 mM, respectively (Moschen et al., 2012), consistent
with increases in acetate transport into brain as serum con-
centrations rise. Cellular acetate provides energy indepen-
dent of TD compromised enzymes (Fig. 13) (Schwer et al.,
2006). Further, chronic EtOH treatment increases blood and
brain acetate and acetyl-CoA (Kiselevski et al., 2003). Inter-
estingly, increases in blood acetate blunt lipopolysaccharide-
induced neuroinflammation (Reisenauer et al., 2011). Thus,
alcoholics consuming EtOH to levels that increase blood ace-
tate providing metabolic energy may be protected against the
TD-induced global metabolic insults, which primarily dis-
rupt glucose metabolism (Fig. 13). Although we did not find
TD-induced neurodegeneration in ENT, TD10 did induce
ENT microglial and astrocyte markers, which appeared nor-
malized by combined EtOH-TD10 treatment consistent with
EtOH-derived acetate blunting ENT glial activation in
EtOH-TD10-treated animals. These findings are consistent
with EtOH-derived acetate blunting the TD-induced meta-
bolic insult and toxicity-induced immune gene induction.
Acetate is transported by MCT (Newman et al., 2011; Su-
zuki et al., 2011). We compared expression of MCT1 and
MCT2 in control THAL and ENT because THAL cell loss
confounds interpretations of levels following treatment. We
found basal expression of both MCT was markedly lower in
THAL than ENT. Previous studies have found low levels of
MCT1 and MCT2 mRNA expression in THAL as well as
Fig. 11. Acetyl-CoA synthetase (AcCoAS) in entorhinal cortex (ENT)
and thalamus (THAL). C57BL/6 mice were treated for 10 days with vehi-
cle, ethanol (EtOH), TD10, or EtOH combined with TD10 (EtOH+TD10) as
described in the Materials and Methods. Brain sections were immuno-
stained with anti-AcCoAS1, an antibody against AcCoAS short-chain fam-
ily member 1. Note all ENT sections have dark AcCoAS1 positive
immunoreactive cells (AcCoAS1 + IR), but not THAL sections.
EtOH+TD10 shows the most AcCoAS1 + IR in both brain regions with
ENT showing greater expression than THAL consistent with EtOH-induced
induction of AcCoAS (Kiselevski et al., 2003; Learn et al., 2003). Scale
bar = 30 lm. TD, thiamine deficiency.
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mammillary bodies and other brain regions sensitive to TD
(Pellerin et al., 1998). LowMCT could also explain the para-
doxical increase in TD-induced THAL degeneration found
during efforts to rescueWE pathology with glucose (Navarro
et al., 2008). In addition to low MCT, we found low levels of
AcCoAS in THAL compared with ENT. LowMCT and Ac-
CoAS could limit acetate metabolism in THAL increasing
the TD THAL metabolic insult relative to ENT and other
brain regions better able to use acetate for energy. We treated
mice with GTA, which is known to increase blood acetate
(Reisenauer et al., 2011). We found elevating acetate with
GTA-reduced TD-induced THAL microglial activation, cell
degeneration, and neuronal loss consistent with acetate par-
tially rescuing THAL from the TD metabolic insult. These
findings present the interesting possibility that acetate sup-
plementation might be used to rescue WE-KS patients,
Fig. 12. Acetate supplementation reduces thiamine deficiency (TD)-induced microglial activation and thalamic degeneration. C57BL/6 mice were trea-
ted with vehicle, glycerin triacetate (GTA), TD10, or GTA+TD10 as described in Materials and Methods. Brain sections were labeled with Iba1 antibody (a
microglial marker), Fluoro-Jade B (a cell death marker), and NeuN antibody (a neuronal marker) (A) Representative images for Iba1 + IR, Fluoro-Jade-B
positive, and NeuN+IR cell. Vehicle-treated microglial showed a resting morphology. TD10 induced dramatic microglial morphology changes in THAL.
GTA+TD10-treated THAL showed less activated microglial morphology than TD10 alone treated THAL (the upper panel). Scale bar = 50 lm. TD10
alone hadmuchmore Fluoro-Jade B positive staining than vehicle in THAL. GTA+TD10 treatment decreased TD10-induced cell death (themiddle panel).
Scale bar = 200 lm. Inset scale bar = 30 lm. NeuN immunoreactivity indicated that TD10 caused significant loss of thalamic neurons, and GTA pre-
vented TD10-induced neuronal loss (the lower panel). Scale bar = 50 lm. (B) Quantification of Fluoro-Jade B fluorescence and NeuN immunoreactivity.
TD10 treatment significantly increased intensity of Fluoro-Jade B fluorescence and number of NeuN+IR cells. GTA significantly reduced TD10-induced
cell death and neuronal loss. **p < 0.01, compared with vehicle controls. #p < 0.05, ##p < 0.01, compared with TD10-treated mice. THAL, thalamus.
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Fig. 13. Thiamine enzymes in acetate and glucose metabolism: Hypothetical role in focal thalamus (THAL) degeneration. (A) Hypothetical impact of
thiamine deficiency on acetate and glucose metabolism. Thiamine-dependent enzymes and metabolic pathways are shown in red, for example, pyruvate
dehydrogenase complex (PDC), pentose phosphate transketolase (PP-TK), and a ketoglutarate dehydrogenase (aKG), a citric acid cycle enzyme. A
comparison of acetate and glucose metabolism indicates both require transporters to enter cells (and the brain), for example, glucose transporters
(GLUT) or monocarboxylic acid transporters (MCT) for glucose and acetate, respectively. Inside the cell, glucose is metabolized to pyruvate and lactate.
Acetyl-CoA formation is critical for citric acid cycle energy production. Acetyl-CoA synthetase (AcCoAS) forms acetyl-CoA from acetate, whereas the
pyruvate dehydrogenase enzyme complex (PDC), which contains thiamine-dependent components, forms acetyl-CoA from pyruvate. Note thiamine
requiring enzymes PP-TK and PDC are key to glucose metabolism for energy. Wernicke-Korsakoff syndrome (WKS) patients may have a genetic predis-
position related to TK. Regardless, thiamine deficiency (TD) disrupts glucosemetabolism for energy more directly than acetate metabolism. (B) Hypothet-
ical mechanism of focal thalamic degeneration due to limited acetate metabolism. Illustrated is ethanol (EtOH) absorption from the gut and metabolism to
acetate in the liver. Both EtOH (black arrows) and acetate (blue arrows) flow through the blood to brain where opposite actions are proposed for THAL
(bottom) compared with entorhinal cortex (cortex). EtOH can prime microglia enhancing proinflammatory gene induction (Crews et al., 2011; Fernandez-
Lizarbe et al., 2009; Qin et al., 2008), whereas acetate can reduce proinflammatory responses (Reisenauer et al., 2011). THAL is illustrated in the bottom
panel. Low levels of MCT and acetyl-CoA synthetase (AcCoAS) cause an initial TD metabolic insult in THAL due to a limited ability of THAL cells to use
EtOH-derived acetate for energy. TD-induced THAL degeneration is accelerated by EtOH due to EtOH priming of microglia proinflammatory responses
(Crews and Vetreno, 2011; Qin et al., 2008) that increase proinflammatory gene transcription accelerating TD-induced degeneration of THAL. In THAL,
low levels of MCT are represented by smaller MCT boxes and reduced astrocyte markers (smaller astrocyte). Microglia become activated by EtOH, neu-
roimmune, and necrosis signals that create positive loops amplifying degeneration leading to THAL cell death and focal WKS lesions. Efforts to use glu-
cose to rescue THAL pathology fail, increasing THAL degeneration likely due to glucose conversion to lactate (Hazell and Butterworth, 2009).
Proinflammatory cytokines increase astrocyte glucose metabolism (Belanger et al., 2011) TD reduces PDC activity leading to extracellular lactate accu-
mulation that is not taken up and metabolized by astrocytes due to low levels of THAL MCT. In contrast, in cortex (top diagram) the TDmetabolic insult is
less due to abundant astrocyte MCT1 and neuronal MCT2 and AcCoAS expression such that acetate provides energy independent of TD compromised
enzymes. EtOH increases brain AcCoAS (Schwer et al., 2006) and acetate can increase acetyl-CoA levels in brain while blunting microglial activation
proinflammatory responses (Reisenauer et al., 2011). Thus, in cortex, the acetate anti-inflammatory microglial response protects against the proinflam-
matory EtOH response. Lactate (brown) released by cells can be taken up by MCT and metabolized for energy likely protecting cortical astrocytes from
the TD insult. Although THAL contains low MCT, increased acetate blunts TD-induced THAL degeneration supporting the hypothesis that THAL focal
degeneration is in part due to decreased THAL ability to use acetate for energy. Acetate may be of benefit to alcoholics with TD.
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although additional studies are needed to further test the role
of MCT and AcCoAS in focal TD-induced degeneration.
In summary, our findings suggest 2 opposing actions of
EtOH on the TD insulted brain (Fig. 13). EtOH itself primes
microglia and proinflammatory TD responses in THAL
accelerating degeneration, whereas acetate formed from
EtOH provides a source of energy independent of TD pro-
tecting cells and alcoholics from the TD-induced loss of glu-
cose-derived energy increasing the chances of thiamine
rescue through dietary sources and survival of TD. Acetate
may represent a potential treatment for acute WE. Addi-
tional studies are needed to understand TD-induced focal
pathology and to determine whether acetate supplementa-
tion can rescue acute WS.
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